All our catalogue prices will be reduced by 10% for the next two months. Use the great opportunity and make sure to place your order before January 31, 2018.
Asper Biogene is pleased to introduce our new testing portfolio of metabolic disorders. Single gene tests as well as multigene panels are included in Asper Metabolic Disorders’ menu. Glycogen and lysosomal storage diseases, fatty acid oxidation disorders, and urea cycle disorders are represented among others.
Full list of tests is available on www.asperbio.com/asper-metabolic-disorders
We have expanded our selection of cardiovascular genetic tests to include tests for different types of dyslipidemias, cardiomyopathies, and arrhythmias. In addition, pulmonary arterial hypertension test has been upgraded with a set of genes to facilitate differential diagnosis. Full list of tests is available: www.asperbio.com/asper-cardiogenetics/
Asper Dysmorphology now includes NGS panel for the diagnostics of skeletal ciliopathies. The panel encompasses testing of different forms of short-rib thoracic dysplasia as well as phenotypically overlapping disorders like cranioectodermal dysplasias. For further information visit www.asperbio.com/skeletal-ciliopathies
Asper Endocrinology testing portfolio has been launched now. Our latest testing selection is designed for the diagnostics of both monogenic, and complex hereditary endocrine disorders.
Since molecular diagnostics has become the daily practice of endocrinology we are to provide valuable tool for clinicians in order to facilitate diagnosing, optimize treatment, and identify at risk family members.
List of the tests is available on www.asperbio.com/asper-endocrinology/
New multigene panel enables testing of autism spectrum disorders by next generation sequencing of 62 genes. View test details and list of genes www.asperbio.com/autism-spectrum-disorders
Melanoma NGS panel is now available. For detailed information see www.asperbio.com/melanoma. Feel free to throw out suggestions for the genes you would like to add to the panel.
Charcot-Marie-Tooth Disease NGS panel has been upgraded with the following genes: ARSA, HINT1, HSPB3, KIF1A, NGF, SCN9A, SLC5A7, SPTLC1, SPTLC2, TFG, TYMP, WNK1.
The new version of the test covers the analysis of 67 genes. Full list of genes is available on www.asperbio.com/cmt.
We wish to inform our clients and partners that Asper Biotech has been acquired by Asper Biogene LLC and is therefore under new management. The business and day-to-day operations will continue to be conducted as usual and the change in ownership will not bring about any changes to client relationships and processes. Corporate identity of the company will be renewed in the near future.
Asper Hematology testing portfolio now includes thrombocytopenia NGS panel. List of 14 genes is available www/asper hematology/thrombocytopenia
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy NGS panel of 14 genes is now available. For further information see Asper Cardiogenetics/ARVD
International meeting on mitochondrial pathology was held in Cologne, 11-15 June.
Poster “Effectiveness of the whole mitochondrial DNA sequencing in patients with suspected mitochondrial disorder” was presented by our clinical geneticist Dr Kairit Joost at the meeting.
Whole Genome Sequencing
We have extended our testing options to whole genome sequencing (WGS). WGS is the most comprehensive tool for identifying the full range of genetic variations. Including the non-coding regions of the genome in the analysis can considerably improve the diagnosing of genetically and phenotypically heterogeneous diseases.
Our high quality data and thorough interpretation of analysis results contribute substantially to diagnosing complex diseases or diseases with atypical phenotype.
Service details are available https://www.asperbio.com/ngs-service/
As Asper Biotech is turning 18 today we would like to thank all our loyal customers and partners for being part of this journey and for supporting us over the years. Though celebrating the anniversary we are still keeping busy with upgrading the testing portfolios. Asper Ophthalmics has been updated with several new tests inquired by our customers. These include NGS panels for anophthalmia/microphthalmia/coloboma/anterior segment dysgenesis and cataract as well as single gene sequencing for Norrie Disease and papillorenal syndrome.
We have upgraded Asper Oncogenetics testing portfolio with NGS panels for Fanconi anemia and thyroid cancer diagnostics. Please see detailed testing information on https://www.asperbio.com/asper-oncogenetics/
New NGS panel covers the analysis of 7 genes associated with pulmonary arterial hypertension. Testing information and list of genes are available on https://www.asperbio.com/asper-cardiogenetics/pulmonary-arterial-hypertension-ngs-panel/.
Today is Rare Disease Day. Over 90 countries worldwide are participating in different events to raise more awareness for rare diseases. Asper Biotech’s representative is attending a roundtable discussion at the Parliament of Estonia about possibilities and challenges within the rare disorders research, provision of medical care and services.
PREDICTION-ADR project close-out meeting was held this week in Tallinn. The meeting was very presentable involving participants from different European countries.
The aim of the PREDICTION-ADR study was to discover the genetic factors predisposing patients to adverse drug reactions from cardiovascular disease drugs. The meeting wrapped up achievements of the project funded by the European Commission. New prospectives for further collaboration of consortium members were considered as well.
The event ended up with an inspiring visit to historical Tallinn Town Hall, the oldest in Scandinavia.
Two new NGS panels are now available – Joubert Syndrome and Neurodegeneration with Brain Iron Accumulation. For further information see https://www.asperbio.com/asper-neurogenetics/.
NGS panel now includes 56 genes associated with different types of Charcot-Marie-Tooth Disease and also other neuropathies. Full list of genes is available on https://www.asperbio.com/asper-neurogenetics/charcot-marie-tooth-disease/charcot-marie-tooth-disease-ngs-panel/
We set about to provide bioinformatic analysis and interpretation of your genetic data. Our highly qualified geneticists are analyzing and interpreting your sequencing data, deletion/duplication analysis results etc.
Our thorough clinical interpretation includes phenotypic and clinical information evaluation; careful classification of variants based on population frequency, variant databases, in-silico prediction models and conservation scores; as well as recommendations for further testing strategies if necessary. Identified findings are reported according to the American College of Medical Genetics and Genomics (ACMG 2015) recommendations.
Ask customized solution from our experienced team to facilitate your clinical practice.
We have improved our Dystonia NGS panel with 29 genes, the new upgraded version now includes 39 genes related to different types of dystonia and syndromes with clinical features of dystonia. New genes added to the panel are associated with dystonia types 2, 3, 4, 11, 23, 24, 25, 26, 27, and disorders such as hypermanganesemia, glutaric aciduria, familial dyskinesia with facial myokymia, neurodegeneration with brain iron accumulation, and others. Full list of the genes covered by the panel is available https://www.asperbio.com/asper-neurogenetics/dystonia/dystonia-ngs-panel/
Asper Neurogenetics portfolio has been expanded with epilepsy NGS panel. The panel covers sequencing of 128 genes associated with different forms of epilepsy, including epileptic encephalopathies, genetic generalized and focal epilepsy syndromes, and related neurodevelopmental conditions. Order here: https://www.asperbio.com/asper-neurogenetics/epilepsy/epilepsy-ngs-panel/
We have launched two new tests in Asper Ophthalmics portfolio – NGS panel for testing different types of glaucoma and RB1 gene sequencing for the diagnostics of retinoblastoma. Learn more https://www.asperbio.com/asper-ophthalmics/
We are glad to invite you to meet our staff at ESHG 2016 (stand #250) in Barcelona, May 21-23. We will be presenting several new tests and services at the exhibition.
To benefit more from our thorough results reports, we’d like to make an excellent offer for our current and new customers. Our diagnostic package service that includes detailed medical interpretation is available with the price of genotyping service for all NGS panels ordered from the beginning of May to the end of June. So, don’t miss to call on our booth to learn more about the new gene panels and services, and let us know how we can improve.
Frontotemporal dementia, Parkinson disease and dystonia gene panels are now listed in the neurogenetics testing menu. Asper Neurogenetics is our fast growing portfolio and most lately added tests have been implemented at the initiative of our customers. We are continually open for your comments and suggestions on new testing panels.
Today Asper Biotech is celebrating it’s 17th year in the field of genetics. We started with offering genetic tests for the diagnostics of inherited eye diseases, and now we have branched out into other specialties as oncology, cardiology, and neurology. Our testing services are constantly expanding to provide valuable and flexible diagnostic solutions to our clients’ practices. We’d like to thank our customers and partners for long-time trust, support and partnership. We’ll keep our tests up-to-date and standards high.
New NGS panel enables analysis of 28 genes known to be associated with hypertrophic cardiomyopathy. The testing panel helps clinicians to identify causative mutations in families meeting diagnostic criteria, and also provides assistance in making differential diagnosis to distinguish hypertrophic cardiomyopathy from other cardiac conditions. Details of the test at https://www.asperbio.com/asper-cardiogenetics/hypertrophic-cardiomyopathy.
We have upgraded our Asper Neurogenetics testing menu with several new gene panels for diagnostics of different forms of craniosynostosis, hereditary spastic paraplegia, and spinocerebellar ataxia.
Craniosynostosis panel includes 7 genes, hereditary spastic paraplegia 34 genes and spinocerebellar ataxia 68 genes. For hereditary spastic paraplegia there is also the targeted mutation analysis of the MT-ATP6 gene available. New testing panels provide valuable input to determine differential diagnosis of the diseases with neurological involvement.
We are offering pre- and post-test genetic consultation (60 €) to referring physicians and health-care professionals. Our medical geneticists are available by email/phone/Skype to provide support in making decisions between different testing possibilities and discussing test results in order to employ a wide range of molecular diagnostics approaches. Contact email@example.com to register for consultation.
We have shortened turnaround times for all NGS panels in order to provide better and faster services to our customers. Genotyping service TAT is 3-6 weeks, diagnostic package with clinical interpretation is available in 6-9 weeks. Additionally, Sanger sequencing and microarray-based analyses are also performed with shorter time, being ready in 2-4 weeks.
The second plenary meeting of the PREDICTION-ADR consortium was held in Uppsala, September 15 and 16, 2015.
On the first day of meeting, the recruitment of patients to both the statin-induced myopathy and the angiotensin-converting inhibitor-induced angioedema arms studies, was discussed. Recruitment of both discovery cohorts has been completed and the focus is now on final recruitment of patients for the replication cohorts.
On day 2 the focus was on sequencing harmonization studies carried out in preparation for sequencing DNA samples in the main studies. Studies at the Universities of Dundee, Liverpool and Uppsala showed very consistent data between all three centers. This means that everything is now ready for sequencing the samples in the principal PREDICTION-ADR studies, which is due to begin.
Prediction-ADR aims to discover the genetic factors predisposing patients to adverse drug reactions from cardiovascular disease drugs. The project has received funding from the European Union’s Seventh Framework Program for research, technological development and demonstration under grant agreement no 602108.
For further information see Prediction-ADR-Newsletter
Progress meeting of the CTCTrap (Circulating Tumor Cells TheRapeutic APheresis) consortium was held in Tallinn, 8-9 Sept. On the first day results of phenotypical characterization and molecular profiling of CTCs were discussed. Talks on project milestones for final year took place next day. The final year sees validation of CTCapheresis for clinical use.
CTCTrap aims to develop safe and effective equipment to collect CTCs from peripheral blood in cancer patients for the molecular characterization of these cells for better diagnostic and treatment options. Furthermore the results of the project provide a new knowledge on metastasis’ mechanism, risk assessment and the optimal therapy choice during the course of the disease of cancer patients.
The CTCTrap consortium consists of 4 Small & Medium Enterprises (SME) and 7 academic institutions and is funded through FP7 health. 2012.1.2-1 #305341.
For further information see CTCTrap newsletter.
Sensorineural hearing loss testing panels are now included into Asper Otogenetics portfolio, which also contains tests for diagnostics of numerous syndromes related to sensorineural and conductive hearing loss. Our multi-gene panels provide clinicians valuable tool for accurate differential diagnosis of syndromes with a similar phenotypic spectrum.
We are glad to launch several new testing portfolios – Asper Cardiogenetics, Asper Neurogenetics, and Asper Wellness. Asper Cardiogenetics covers genetic tests related to cardiovascular diseases, including Long QT syndrome, Marfan syndrome, Noonan syndrome, as well as tests for prediction of adverse drug reactions. Asper Neurogenetics includes genetic tests for the diagnostics of diseases with neurologic and metabolic involvement.
Tests for determining disease risks, food intolerance, and athletic performance can be found in Asper Wellness portfolio.
Genetic conditions assembled in new testing menus are detectable mainly by multi-gene panels, but single gene testing and targeted mutation analysis are also available.
Visit Asper Biotech at ESHG 2015 (stand #644) in Glasgow, June 6-9. We are about to launch several new testing portfolios, targeting to cardiac disorders, neurological diseases and hereditary hearing loss related syndromes. Come talk to us about testing approaches that would be useful to your clinical practice, and check out our new tests.
We are looking forward to meeting you in Glasgow!
We have expanded AMD testing panel with 11 new genes. The updated next generation sequencing panel now comprises 21 genes (ABCA4, ARMS2, C2, C3, C9, CCR3, CFB, CFH, CFI, CST3, CXCL8, CX3CR1, ERCC6, FBLN5, HMCN1, HTRA1, IL6, IL1A, NLRP3, RAX2, TLR4) associated with AMD. Targeted mutation analysis is also available.
Eneli Oitmaa, the CEO of Asper Biotech gives an interview to the CE biotech.com about the current situation in genetic testing services in Asper Biotech and also company’s future perspectives in biotechnology market. Read the interview: http://cebiotech.com/articles/Asper-biotech-and-estonian-biotechnology-sector,300
We have added six new genes (CBL, HRAS, KAT6B, MAP2K2, SHOC2, SPRED1) to the Noonan syndrome NGS panel. Now the panel includes 13 genes associated with Noonan syndrome and Noonan spectrum disorders.
As we highly appreciate our customers’ feedback on our services, we have added two new tests to the testing menu based on the results of the resent customer survey. The Charcot-Marie-Tooth Disease test uses massively parallel sequencing to analyze as many as 30 disease-associated genes. This approach allows distinguishing various forms of the disease and therefore preventing serial single gene testing. Deletion/duplication analysis of the PMP22 gene in the 17p11.2-12 region is also available. The duplications in this region could account for approximately 75 % of cases.
For Menkes disease testing we use Sanger sequencing to detect disease-causing mutations in the ATP7A gene.